JONTISAVE
(Zoledronic Acid Monohydrate) B.P
Clinical Benefits
Reduces the risk of vertebral, hip, and other fractures
Enhances patient compliance with annual dosing
Proven to reduce bone turnover markers
Suitable for postmenopausal osteoporosis, Paget’s disease,and glucocorticoid-induced osteoporosis
Features & Benefits
Potent bisphosphonate with once-yearly dosing
Convenient 100ml ready-to-infuse vial
High affinity for bone tissue – long-lasting action
Ideal for patients with poor oral bisphosphonate tolerance
Improves bone mineral density (BMD)
Mode of Action
Zoledronic acid acts by inhibiting osteoclast – mediated bone resorption. It binds to bone hydroxyapatite and disrupts the mevalonate pathway in osteoclasts by inhibiting farnesyl pyrophosphate synthase. This leads to osteoclast apoptosis, thereby reducing bone loss and increasing bone mass and strength.
Pharmacological Highlights
Half-life:
Approximately 146 hours (terminal half-life in bone)
Binding
Strong affinity for bone mineral (hydroxyapatite)
Dosing Frequency:
Once-yearly intravenous infusion.
Bioavailability:
100% via IV administration
Onset of Action:
Rapid suppression of bone resorption within days
Mechanism:
Inhibits osteoclast activity via the mevalonate pathway
Excretion:
Primarily renal (unchanged drug via urine)
